| Typicality: | 0.380 |
| Saliency: | 0.304 |
| for treating patients | 5 | purpose |
| in 2001 | 5 | temporal |
| in both children | 2 | other |
| use → be approved by → the fda | 25 |
| use → approved by → fda | 8 |
| use → be approved by → fda | 6 |
| negative | neutral | positive |
| 0.207 | 0.603 | 0.190 |
| Raw frequency | 39 |
| Normalized frequency | 0.304 |
| Modifier score | 0.500 |
| Perplexity | 24.927 |